W
WSI Co Ltd
KOSDAQ:299170
WSI Co Ltd
KOSDAQ:299170
Price:
3 210
KRW
Market Cap:
₩133.2B
WSI Co Ltd
Note Receivable
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
WSI Co Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
W
|
WSI Co Ltd
KOSDAQ:299170
|
Note Receivable
₩480m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Chorokbaem Healthcare Co Ltd
KRX:118000
|
Note Receivable
₩22.1m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
W
|
Wonik Co Ltd
KOSDAQ:032940
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
Note Receivable
₩157.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-28%
|
|
|
B
|
BlueMTec Co Ltd
KOSDAQ:439580
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
WSI Co Ltd
Glance View
WSI Co., Ltd. manufactures medical devices and pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-09-21. The firm mainly distributes the topical hemostatic agent Flosils. In addition, the Company supplies endoscopes related to spinal surgery, anti-adhesion agents, and bone hemostatic agents.
Intrinsic Value
1 696.71
KRW
Overvaluation 47%
W
See Also
What is WSI Co Ltd's Note Receivable?
Note Receivable
480m
KRW
480m
KRW
Based on the financial report for Dec 31, 2024, WSI Co Ltd's Note Receivable amounts to 480m KRW.
What is WSI Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 1Y
269%
269%
Over the last year, the Note Receivable growth was 269%.
